Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.18    0.00 (0.00%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £2.38m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

26 Sep 2006 16:46

Azure Holdings PLC26 September 2006 Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2006 Chairman's statement I am pleased to present the interim accounts for the six months ended 30 June2006. In the six months to 30 June 2006 the Company announced a loss after taxation of£138,000 (2005: £74,000). The figures should not reflect the future of the Company, which hopefully willmove forward successfully as ValiRx plc from early next month, because, asannounced on 11 September 2006, the reverse acquisition of ValiRx Limited hasbeen agreed and is subject to shareholders approval at the EGM scheduled for 2October 2006. If all the resolutions at that meeting are approved, the Company will retain itsAIM quotation and I will resign as Chairman leaving the new board and GerryDesler, Finance Director from the old board, to run the Company. Barry GoldChairman 26 September 2006 Azure Holdings plc Profit and Loss Account for the six months ended 30 June 2006 6 months ended 6 months ended Year ended 31 30 June 2006 30 June 2005 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000 Turnover - - - Administrative expenses (138) (74) (134) Operating loss (138) (74) (134) Loss on ordinary activities before taxation (138) (74) (134) Tax on loss on ordinary activities - - - Loss on ordinary activities after taxation (138) (74) (134) Retained loss for the period (138) (74) (134) Loss per ordinary share (0.12p) (0.15p) (0.28p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains and losses. Azure Holdings plc Balance Sheet as at 30 June 2006 30 June 2006 30 June 2005 31 December 2005 (unaudited) (unaudited) (audited) £'000 £'000 £'000Current assetsDebtors 9 3 1Cash at bank and in hand 127 1 1 136 4 2 Creditors: amounts falling due within one year (103) (147) (205) Net current assets/(liabilities) 33 (143) (203) Total assets less current liabilities 33 (143) (203) Net (liabilities)/assets 33 (143) (203) Capital and reservesCalled up Share Capital 6,271 5,475 5,475Share Premium 9,858 10,279 10,279Profit and loss account (16,096) (15,897) (15,957) Equity shareholders funds 33 (143) (203) Azure Holdings plc Cash Flow Statement for the six months ended 30 June 2006 6 months ended 6 months ended 30 June 2006 30 June 2005 (unaudited) (unaudited) £'000 £'000Net cash inflow (outflow) from operating activities (249) (13) FinancingIssue of ordinary shares 796 - Share premium reduction arising onconversion of loan stock (421) - Increase/(Decrease) in cash 126 (13) Azure Holdings plc Notes to the Interim Results 1. The interim results are unaudited and do not constitute statutoryaccounts within the meaning of section 240 of the Companies Act 1985. Thefigures for the year ended 31 December 2005 have been extracted from thestatutory accounts filed with the registrar of companies on which the auditorsgave an unqualified report. 2. The interim results have been prepared using the accountingpolicies set out in the statutory accounts for the year ended 31 December 2005. 3. The comparative figures for the unaudited interim results for theperiod ended 30 June 2005 are stated as announced on 27 September 2005. 4. Loss per share The loss per share for the six months ended 30 June 2006 has been calculated onthe basis of the loss after taxation for the period of £138,000 (2005: £74,000) and the weighted average number of shares in issue during the period of118,717,810 (2005: 48,317,569). . 5. The directors do not propose to pay a dividend for the period. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th May 20182:56 pmRNSHolding(s) in Company
8th May 201812:13 pmRNSResult of AGM
4th May 20184:40 pmRNSSecond Price Monitoring Extn
4th May 20184:35 pmRNSPrice Monitoring Extension
4th May 20184:01 pmRNSPlacing and grant of warrants
26th Apr 20182:05 pmRNSSecond Price Monitoring Extn
26th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20184:40 pmRNSSecond Price Monitoring Extn
25th Apr 20184:35 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSEU Patent Grant for Therapeutic Compound, VAL201
20th Apr 201810:45 amEQSHardman & Co Research: ValiRx (VAL): 2017: a pivotal year
19th Apr 20187:00 amRNSGENEICE & VAL101 Update
12th Apr 20187:00 amRNSNotice of AGM
10th Apr 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSUS Patent Grant for Therapeutic Compound, VAL201
19th Mar 20187:00 amRNSHolding(s) in Company
16th Mar 20183:01 pmRNSAppointment of Broker
2nd Mar 201811:01 amRNSStatement re broker
9th Feb 201811:57 amRNSIssue of options and directors dealings
2nd Feb 20184:26 pmRNSHolding(s) in Company
25th Jan 201812:06 pmRNSHolding(s) in Company
23rd Jan 20183:30 pmRNSHolding(s) in Company
16th Jan 20187:00 amRNSValiSeek Clinical Update (VAL401)
11th Jan 20187:00 amRNSUS Patent Notice of Allowance for Compound VAL201
4th Jan 20182:29 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSExercise of Warrants and Issue of Equity
27th Dec 201712:54 pmRNSFinal Loan Note Conversion and Issue of Equity
22nd Dec 20177:00 amRNSIssue of Equity
21st Dec 20179:16 amRNSResult of General Meeting
20th Dec 20173:58 pmRNSWarrant Exercise
20th Dec 20173:03 pmRNSWarrant Exercise
18th Dec 20178:45 amRNSWarrant Exercise
18th Dec 20177:00 amRNSre: VAL201 Clinical Trials
15th Dec 20177:00 amRNSExercise of Warrants and Issue of Equity
12th Dec 20177:00 amRNSValiSeek Clinical Development Update
11th Dec 20173:48 pmRNSLoan Note Conversion and Issue of Equity
6th Dec 20177:00 amRNSShareholder Circular and Notice of General Meeting
30th Nov 20172:38 pmRNSIssue of Equity
20th Nov 201711:23 amRNSHolding(s) in Company
15th Nov 20174:37 pmRNSYorkville CLN Conversion
11th Oct 20177:00 amRNSNotification of US Patent Allowance
5th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSTotal Voting Rights
28th Sep 20177:00 amRNSValiSeek Clinical Development Update
27th Sep 20173:32 pmRNSHolding(s) in Company
26th Sep 20177:00 amRNSHalf-year Report
20th Sep 20173:18 pmRNSVAL201 update
19th Sep 20177:00 amRNSIssue of Equity
13th Sep 20179:34 amRNSHardman Research: GeneICE and VAL101 progress
7th Sep 20177:00 amRNSGeneICE & VAL101 Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.